Gestational diabetes & diabetes in pregnancy
Who Benefits Most from Advanced Hybrid Closed Loop Therapy in Pregnancy Across Different Subgroups: A Secondary Analysis of the Randomized Controlled CRISTAL Trial
Authors' conclusion
AHCL therapy improved glycemic management in pregnant women with baseline HbA1c <7.0%, in women without prior AHCL use, and in women without higher education, indicating that AHCL might particularly benefit these subgroups.
Study context
- Population
- Pregnant women with T1D in the CRISTAL trial, subgroups defined by baseline characteristics
- Comparison
- Advanced hybrid closed loop (AHCL) vs standard insulin therapy
- Primary endpoint
- Glycemic outcomes (TIRp, TIRp overnight, TBRp, TBRp overnight) within subgroups
- Follow-up
- Averaged over the antenatal period (14-, 20-, 26-, and 33-weeks' gestation)
Methodological detailssubgroup analysis
- Subgroup analysis
Primary result
As reported in the abstract
TIRp by subgroup · antenatal period average
AHCL vs SoCEstimate (95% CI)
Baseline HbA1c <7.0% (n = 35 vs n = 37); TIRp higher with AHCL; 1 h 21 min more TIRp per day
mean difference 5.64 %(1.32–9.96)
TIRp overnight, baseline HbA1c <7.0%; higher with AHCL
difference 11.89 %(7.01–16.76)
No prior AHCL use (n = 24 vs n = 28); TIRp higher with AHCL
difference 6.29 %(0.90–11.68)
TIRp overnight, no prior AHCL use; higher with AHCL
difference 11.91 %(5.65–18.16)
Without higher education (n = 14 vs n = 14); TIRp higher with AHCL
difference 7.33 %(0.88–13.78)
Original publication
Who Benefits Most from Advanced Hybrid Closed Loop Therapy in Pregnancy Across Different Subgroups: A Secondary Analysis of the Randomized Controlled CRISTAL Trial. Diabetes Technol Ther. Published 23 September 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →